Liver-specific MR contrast agents: current status and prospects

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Liver-specific MR contrast agents include superparamagnetic iron oxide (SPIO) particles and hepatobiliary paramagnetic agents. SPIO particles are phagocytosed by reticuloendothelial cells in the liver, resulting in negative enhancement of the liver parenchyma on T2- or T2*-weighted images. Ferumoxides and related iron oxide formulations have been tested clinically throughout the world, and have been demonstrated to improve the detection and characterization of hepatic neoplasms. Hepatobiliary paramagnetic agents are partially taken up by hepatocytes, yielding positive, sustained enhancement of the liver parenchyma on T1-weighted images. These agents are referred to as "value-added" versions of extracellular gadolinium compounds because they increase tumor-liver contrast in both the perfusion phase and hepatobiliary phase. Although only ferumoxides are currently available for clinical use, many agents are in the pipeline. The possibility of "one-stop shopping" diagnosis by liver-specific MR contrast agents is an attractive alternative to the existing multistep diagnosis in liver imaging. Further studies to analyze the cost-benefit ratio will follow, to determine whether liver-specific MR contrast agents lead to change in patient treatment and whether such a decision would be reliable.

Original languageEnglish
Pages (from-to)525-533
Number of pages9
JournalNippon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica
Volume61
Issue number10
Publication statusPublished - 2001 Sep

Fingerprint

Contrast Media
Liver
Cytophagocytosis
Gadolinium
Liver Neoplasms
Cost-Benefit Analysis
Hepatocytes
Perfusion
ferric oxide
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Liver-specific MR contrast agents : current status and prospects. / Tanimoto, Akihiro.

In: Nippon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica, Vol. 61, No. 10, 09.2001, p. 525-533.

Research output: Contribution to journalArticle

@article{236014f11da14705ab8a228cd31cae85,
title = "Liver-specific MR contrast agents: current status and prospects",
abstract = "Liver-specific MR contrast agents include superparamagnetic iron oxide (SPIO) particles and hepatobiliary paramagnetic agents. SPIO particles are phagocytosed by reticuloendothelial cells in the liver, resulting in negative enhancement of the liver parenchyma on T2- or T2*-weighted images. Ferumoxides and related iron oxide formulations have been tested clinically throughout the world, and have been demonstrated to improve the detection and characterization of hepatic neoplasms. Hepatobiliary paramagnetic agents are partially taken up by hepatocytes, yielding positive, sustained enhancement of the liver parenchyma on T1-weighted images. These agents are referred to as {"}value-added{"} versions of extracellular gadolinium compounds because they increase tumor-liver contrast in both the perfusion phase and hepatobiliary phase. Although only ferumoxides are currently available for clinical use, many agents are in the pipeline. The possibility of {"}one-stop shopping{"} diagnosis by liver-specific MR contrast agents is an attractive alternative to the existing multistep diagnosis in liver imaging. Further studies to analyze the cost-benefit ratio will follow, to determine whether liver-specific MR contrast agents lead to change in patient treatment and whether such a decision would be reliable.",
author = "Akihiro Tanimoto",
year = "2001",
month = "9",
language = "English",
volume = "61",
pages = "525--533",
journal = "Nippon Acta Radiologica",
issn = "0048-0428",
publisher = "Japan Radiological Society",
number = "10",

}

TY - JOUR

T1 - Liver-specific MR contrast agents

T2 - current status and prospects

AU - Tanimoto, Akihiro

PY - 2001/9

Y1 - 2001/9

N2 - Liver-specific MR contrast agents include superparamagnetic iron oxide (SPIO) particles and hepatobiliary paramagnetic agents. SPIO particles are phagocytosed by reticuloendothelial cells in the liver, resulting in negative enhancement of the liver parenchyma on T2- or T2*-weighted images. Ferumoxides and related iron oxide formulations have been tested clinically throughout the world, and have been demonstrated to improve the detection and characterization of hepatic neoplasms. Hepatobiliary paramagnetic agents are partially taken up by hepatocytes, yielding positive, sustained enhancement of the liver parenchyma on T1-weighted images. These agents are referred to as "value-added" versions of extracellular gadolinium compounds because they increase tumor-liver contrast in both the perfusion phase and hepatobiliary phase. Although only ferumoxides are currently available for clinical use, many agents are in the pipeline. The possibility of "one-stop shopping" diagnosis by liver-specific MR contrast agents is an attractive alternative to the existing multistep diagnosis in liver imaging. Further studies to analyze the cost-benefit ratio will follow, to determine whether liver-specific MR contrast agents lead to change in patient treatment and whether such a decision would be reliable.

AB - Liver-specific MR contrast agents include superparamagnetic iron oxide (SPIO) particles and hepatobiliary paramagnetic agents. SPIO particles are phagocytosed by reticuloendothelial cells in the liver, resulting in negative enhancement of the liver parenchyma on T2- or T2*-weighted images. Ferumoxides and related iron oxide formulations have been tested clinically throughout the world, and have been demonstrated to improve the detection and characterization of hepatic neoplasms. Hepatobiliary paramagnetic agents are partially taken up by hepatocytes, yielding positive, sustained enhancement of the liver parenchyma on T1-weighted images. These agents are referred to as "value-added" versions of extracellular gadolinium compounds because they increase tumor-liver contrast in both the perfusion phase and hepatobiliary phase. Although only ferumoxides are currently available for clinical use, many agents are in the pipeline. The possibility of "one-stop shopping" diagnosis by liver-specific MR contrast agents is an attractive alternative to the existing multistep diagnosis in liver imaging. Further studies to analyze the cost-benefit ratio will follow, to determine whether liver-specific MR contrast agents lead to change in patient treatment and whether such a decision would be reliable.

UR - http://www.scopus.com/inward/record.url?scp=0035460322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035460322&partnerID=8YFLogxK

M3 - Article

C2 - 11676169

AN - SCOPUS:0035460322

VL - 61

SP - 525

EP - 533

JO - Nippon Acta Radiologica

JF - Nippon Acta Radiologica

SN - 0048-0428

IS - 10

ER -